University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy : an economic evaluation based on data from the LENS trial

Simple item page
dc.contributor.authorScotland, Graham
dc.contributor.authorTsehaye, Mekazin
dc.contributor.authorStyles, Caroline
dc.contributor.authorLogue, Jennifer
dc.contributor.authorSammons, Emily
dc.contributor.authorZayed, Mohammed
dc.contributor.authorEmberson, Jonathan
dc.contributor.authorWade, Rachel
dc.contributor.authorWallendszus, Karl
dc.contributor.authorStevens, Will
dc.contributor.authorCretney, Rosanna
dc.contributor.authorHarding, Simon
dc.contributor.authorLeese, Graham
dc.contributor.authorCurrie, Gemma
dc.contributor.authorArmitage, Jane
dc.contributor.authorPreiss, David
dc.contributor.authorLENS collaborative group
dc.contributor.institutionUniversity of Aberdeen.Health Economics Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2025-08-15T07:55:02Z
dc.date.available2025-08-15T07:55:02Z
dc.date.issued2025-09
dc.descriptionOpen Access via the Wiley agreement We are very grateful to all participants, staff at participating NHS Scotland sites, and members of the Steering Committee and Data Monitoring Committee. We greatly appreciate the support of NHS Scotland’s Diabetic Eye Screening program, the Scottish Care Information Diabetes Collaboration (SCI Diabetes), Public Health Scotland’s electronic Data Research and Innovation Service (eDRIS), the Health Informatics Centre at the University of Dundee, and PCI Pharma Services. We are also very grateful to Prof Sobha Sivaprasad, University College London, for providing clinical expert opinion on economic modelling assumptions.en
dc.description.statusPeer revieweden
dc.format.extent14
dc.format.extent1292387
dc.identifier304780536
dc.identifierdf45e8a7-ea6a-4594-aef2-f562c6014bad
dc.identifier105011182110
dc.identifier.citationScotland, G, Tsehaye, M, Styles, C, Logue, J, Sammons, E, Zayed, M, Emberson, J, Wade, R, Wallendszus, K, Stevens, W, Cretney, R, Harding, S, Leese, G, Currie, G, Armitage, J, Preiss, D & LENS collaborative group 2025, 'Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy : an economic evaluation based on data from the LENS trial', Diabetic Medicine, vol. 42, no. 9, e70098. https://doi.org/10.1111/dme.70098en
dc.identifier.doi10.1111/dme.70098
dc.identifier.iss9en
dc.identifier.issn0742-3071
dc.identifier.urihttps://hdl.handle.net/2164/25861
dc.identifier.vol42en
dc.language.isoeng
dc.relation.ispartofDiabetic Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectDiabetic Retinopathyen
dc.subjectFenofibrateen
dc.subjectCost-effectiveness analysisen
dc.subjectR Medicine (General)en
dc.subject.lccR1en
dc.titleCost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy : an economic evaluation based on data from the LENS trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Scotland_etal_DM_Cost-effectiveness_of_Fenofibrate_VOR.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Download

Collections

All research